CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Jun. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 852.4	$ 597.3
Trade receivables, net	2,732.5	2,686.9
Inventories, net	1,336.7	1,256.6
Prepaid expenses and other current assets	896.8	966.4
Total current assets	5,818.4	5,507.2
Property, plant and equipment, net	1,472.1	1,441.8
Intangible assets, net	21,335.8	23,083.0
Goodwill	18,511.8	18,552.8
Deferred tax assets, net	304.7	156.0
Other long-term assets, net	219.4	223.7
Total assets	47,662.2	48,964.5
Current liabilities:
Accounts payable	425.9	433.7
Accrued and other current liabilities	3,335.5	3,859.1
Acquisition-related contingent consideration	170.9	196.8
Current portion of long-term debt	294.1	823.0
Total current liabilities	4,226.4	5,312.6
Acquisition-related contingent consideration	903.7	959.1
Long-term debt	30,773.2	30,265.4
Pension and other benefit liabilities	191.6	190.4
Liabilities for uncertain tax positions	116.3	120.2
Deferred tax liabilities, net	5,879.2	5,902.4
Other long-term liabilities	168.7	184.6
Total liabilities	42,259.1	42,934.7
Commitments and contingencies
Equity
Common shares, no par value, unlimited shares authorized, 343,030,673 and 342,926,531 issued and outstanding at June 30, 2016 and December 31, 2015, respectively	9,914.9	9,897.4
Additional paid-in capital	380.4	304.9
Accumulated deficit	(3,425.7)	(2,749.7)
Accumulated other comprehensive loss	(1,573.7)	(1,541.6)
Total Valeant Pharmaceuticals International, Inc. shareholders’ equity	5,295.9	5,911.0
Noncontrolling interest	107.2	118.8
Total equity	5,403.1	6,029.8
Total liabilities and equity	$ 47,662.2	$ 48,964.5